10:00 AM EST - QLT Inc. : announced today positive preliminary results from its Phase 1b proof-of-concept clinical trial of QLT091001 for the treatment of Leber Congenital Amaurosis (LCA), a rare and disabling childhood blindness. Analysis of data from 12 subjects with LCA who were treated with QLT091001 for seven days has been conducted to determine improvements in two distinct measures of visual function: visual acuity and visual fields. QLT Inc.
shares V.QLT are trading up $0.68 at $8.36.
